Completed study

Official Study Title
Efficiency in management of organ dysfunction associated with infection by the novel SARS-Cov-2 virus through A PErsonalized immunotherapy approach

Brief Description
ESCAPE is an open non-randomized clinical trial aiming to the personalized therapy of patients with COVID-19. Using biomarkers, enrolled patients are receiving treatment with intravenous anakinra or intravenous tocilizumab.

Status: Completed
Study Type: Interventional (Clinical Trial)
Study phase: II
Study sites: 17  sites in Greece
Actual enrolment: 102 participants Identifier: NCT04339712
EudraCT number: 2020-001039-29
National Organization for Medicines Approval: IS021-20
National Ethics Committee Approval: 30/20

Study Start: April 2020
Study Completion: January 2021

Condition/Disease studied: COVID-19; Virus Diseases; Macrophage Activation Syndrome; Corona Virus Infection
Keywords: COVID-19; SARS-CoV-2; MAS; anakinra; Tocilizumab

Related publications